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Abstract
Introduction
Non-adherence to disease-modifying antirheumatic drugs (DMARDs) is suspected to
relate to health care costs. In this study we investigated this relation in the first year of
treatment.
Methods
In a multi-center cohort study with a one year follow up, non-adherence was continuously
measured using electronic monitored medication jars. Non-adherence was defined as the
number of days with a negative difference between expected and observed opening of the
container. Cost measurement focused on hospital costs in the first year: consultations,
emergency room visits, hospitalization, medical procedures, imaging modalities, medication
costs, and laboratory tests. Cost volumes were registered from patient medical files. We
applied multivariate regression analyses for the association between non-adherence and
costs, and other variables (age, sex, center, baseline disease activity, diagnosis, socioeco-
nomic status, anxiety and depression) and costs.
Results
Of the 275 invited patients, 206 were willing to participate. 74.2% had rheumatoid arthritis,
20.9% had psoriatic arthritis and 4.9% undifferentiated arthritis. 23.7% of the patients
were more than 20% non-adherent over the follow-up period. Mean costs are € 2117.25
(SD € 3020.32). Non-adherence was positively related to costs in addition to baseline
anxiety.
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Conclusion
Non-adherence is associated with health care costs in the first year of treatment for arthritis.
This suggests that improving adherence is not only associated with better outcome, but also
with savings.
Introduction
Reviews have shown that in rheumatoid arthritis (RA), 49% to 99% of patients are adherent,
depending on the measurement method of adherence [1]. Up till now, it is unclear what the
actual impact of non-adherence to disease-modifying antirheumatic drugs (DMARDs) is to
direct health care expenditures. Non-adherence to DMARDs is suspected to increase health
care costs [2]. The aim of this study is 1) to examine the magnitude of the health care costs for
inflammatory arthritis in the first year after diagnosis and 2) to determine whether non-adher-
ence to DMARDs has an impact on health care costs.
Health care expenditures for rheumatoid arthritis care comprise of 0.6% of the Dutch
healthcare expenditures [3]. These costs consist of 51% medication and aids for rheumatoid
arthritis, 19% elderly care, 18% hospital care and 9% primary care (GP visits) [3]. Healthcare
costs for RA impose a burden on individual RA patients, health services and society [4]. Stud-
ies suggest that drug treatment reduces overall healthcare costs by reducing patients’ need for
expensive medical services such as hospitalization and emergency room (ER) treatment [5].
This observation also suggests that improved adherence reduces health care costs.
Over the last decades the outcome for early arthritis has improved tremendously, since it is
treated timely and intensively, following the treat to target principle [6, 7]. The primary target
for treatment is to reach a state of clinical remission or at least a state of low disease activity.
With a timely and intensive treatment in the first year after diagnosis, remission can be reached.
This intensive treatment will benefit the long term disease outcome. Therefore, drug therapy is
given in an early phase, which consists of DMARDs and corticosteroids [7]. Until the desired
treatment target is reached, drug therapy should be adjusted at least every 3 months [6, 7].
When treatment with conventional, synthetic DMARDs fails, a first step-up will be made to
higher DMARD dosages or additional DMARDs. This can, for some patients, lead to undesir-
able side effects, such as gastro-intestinal problems, liver or kidney abnormalities [8]. When
this occurs, patients may be referred to other medical specialists, which causes more health
care expenditures. When step-ups to conventional DMARDs fail, a step-up to treatment with
advanced, but also much more expensive biologicals will be made. That suggests that especially
in the first year of treatment, adherence is related to treatment success and costs.
Non-adherence can be expected to cause either more or less health care costs. Usually, the
relation in which non-adherence leads to ineffective treatment and higher costs due to substi-
tuting expensive treatment, is emphasized. Indeed, the burden of a complex and inconvenient
dosing regimen, which commonly causes side-effects, has a negative impact on adherence to
treatment and this can hamper to achieve the full benefits of the therapy and logically to poorer
long-term outcomes [9–12]. Symptoms and complications may worsen, leading to increased
use of hospital and emergency room (ER) services, office visits, and other medical resources
[13]. Non-adherence can also imply that money has been wasted for unused medication [10].
On the other hand, non-adherence to DMARDs might also lead to less experienced side-
effects. Patients reported that if side-effects outweigh the experienced benefits of the treatment,
this is one of the reasons for them to stop taking the medication [14]. This might mean that
non-adherent patients are less often referred to medical specialists because of adverse events.
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From previous studies it is also known that a small amount of patients are not only non-adher-
ent to medication, but also to rheumatologist appointments. These patients avoid health care
consumption and might therefore cause even less direct health care expenditures, regardless of
possible worsening of their disease activity.
In this study we investigated the hospital costs of PsA, RA and undifferentiated arthritis in
the first year after diagnosis and its association with adherence.
Patients and methods
Patients
From an ongoing adherence cohort study with a one year follow-up, we selected the patients
who had finished their participation in the study between March 2013 and December 2014.
Patients were recruited in 11 regional hospitals in the Southwest of the Netherlands. The hospi-
tals consisted of one academic hospital, one specialized clinic and 9 general hospitals. Patients
were included if they were newly diagnosed with RA, psoriatric arthritis (PsA) or undifferenti-
ated arthritis, started using DMARD therapy for the first time, were at least 18 years old, and
were able to read and understand sufficient Dutch. Fig 1 shows the timeline and study set-up.
Within two weeks of starting DMARD therapy, patients were included in the study. Clinical
variables were assessed at baseline (diagnosis, symptom duration before diagnosis, anti-cyclic
citrullinated peptide antibodies (ACPA), Rheumatoid factor and joint involvement) and every
three months (28-joint count disease activity score (DAS28)) by a specialized rheumatology
nurse or a research nurse. At baseline, patients filled out the Hospital Anxiety and Depression
scale (HADS) [15], which consists of two subscales: one for anxiety and one for depression. The
scores range between 0 and 21, higher scores indicating more symptoms of anxiety or depres-
sion. At baseline, the Health Assessment Questionnaire (HAQ) [16] was filled out to measure
physical functioning. This self-administered questionnaire is a validated measure of disability
which includes 20 specific functions that are grouped into categories: dressing and grooming,
arising, eating, walking, personal hygiene, reaching, gripping and other activities. The average
of these scores represents a physical functioning score. HAQ scores range from 0 (no difficulty)
to 3 (unable to do).
Non-adherence measurement
Non-adherence was continuously measured using Medication Event Monitoring System
(MEMS) devices, which consist of a medication vial and a MEMS lid with a microprocessor to
record the day and time of each vial opening. Participants in the study received at the start of
the study for each DMARD a MEMS, which was filled by the pharmacist or the specialized
nurse.The data stored in the MEMS lid was every three months transferred by the specialized
nurse into a web-based data platform. This data platform compiles hour-by-hour drug dosing
histories over extended periods, also noting medication regimen changes. Nursing and medi-
cal staff were blind to the adherence data throughout the study.
Extra openings of the MEMS cap will be ignored, because these are mostly not representing
medication intake, but openings by pharmacists. This could otherwise lead to an overestima-
tion of adherence. Each day when the medication cap was not opened when it should have
been opened, was assigned as a non-adherence event. When a patient stopped taking their
DMARD medication on rheumatologist advice, for example in the case of lab abnormalities,
this was not assigned as a non-adherence event. For the whole one-year period an underuse
proportion was calculated by adding all days in which non-adherence occurred and dividing
these by the number of days in the observation period. If a patient used multiple DMARDs in
the one-year follow-up period, the mean of the DMARD underuse proportions was calculated.
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Ethics statement
The Erasmus MC Medical Ethics board approved this study. The hospitals’ board of directors
of the Bronovo, Haga hospital, Groene Hart, Amphia, Sint Maartenskliniek, Sint Antonius,
Reinier de Graaf Gasthuis, Sint Franciscus Gasthuis, Lievensberg and Franciscus hospital gave
their consent for participation in the study. All participants gave written informed consent for
their participation and for looking up clinical data in their patient files.
Estimating direct healthcare volumes
In health economics, preferably all costs associated with the treatment are included. This
would include not only the treatment costs made in the hospital, but also medical costs made
outside the hospital, travel costs and costs of productivity loss. However, in this investigation
Fig 1. Flowchart of respondents.
doi:10.1371/journal.pone.0171070.g001
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we had only access to hospital files. These hospital files contain information about care at the
department of rheumatology and the other departments in the hospital.
Healthcare volumes were extracted from the patient hospital files by two investigators (AP,
CVS) from the date of diagnosis until one year after diagnosis. We only extracted information
from the patient files from the hospital in which the patient went to the rheumatology outpa-
tient clinic. The number and type of DMARDs (including prednisone) used were derived
from an online system in which the rheumatology nurse had entered the prescribed DMARDs,
dosage and regimen during the one year follow up period.
To gain more insight in which costs are affected by adherence, the healthcare volumes were
divided into three categories: rheumatology outpatient clinic care, rheumatology referral hos-
pital care (including rheumatology outpatient clinic care) and total hospital healthcare vol-
umes (including the rheumatology clinic and rheumatology referral care). Healthcare volumes
were subdivided into: a) consultations (including telephonic patient consultations), b) medical
procedures (therapeutic as well as diagnostic), c) imaging modalities, d) admissions (including
day admissions), and e) ER visits. For rheumatology outpatient healthcare, we also subdivided
into f) laboratory costs, and g) medication costs (costs for synthetic and biologic DMARDs,
costs for prednisone). For visits to other specialists, no data was available on laboratory costs
and medication costs.
The number of comorbidities per patient was measured as the number of separate medical
specialists the patient went to without being referred by the rheumatologist. Due to time con-
straints it was impossible to register per individual patient all types of blood tests that were
conducted in one year. Because the standard strategies of rheumatology lab monitoring differ
per hospital, we randomly selected a number of 10 patients per hospital to determine which set
of laboratory tests are commonly conducted. We calculated the total costs for these test sets
and then counted per patient how many times laboratory tests were requested for monitoring.
Unit prices
To assign unit prices to the different cost categories we used costs derived from the Dutch
manual for cost of illness studies [17] and the Dutch price list for medical treatments, supple-
ment 2 [18]. For medication costs, we used the Dutch price list for medication [19]. In case of
the existence of different medicine manufacturers, the mean medication price was used. All
unit prices were corrected for inflation to June 2014 using the inflation numbers from the Cen-
tral Bureau of Statistics [20].
Statistical analyses
We used univariate descriptive measures to report demographic and disease characteristics of
the study population. Statistical comparison of the baseline characteristics between patients
lost to follow up and patients with complete follow up were made with Student t-tests and chi
square tests. Cost data is usually skewed, with some patients making much more costs that the
mode. To allow for a multivariable analysis, we transformed the cost and adherence data, since
both are heavily skewed. A rank transformation was chosen to allow for normal distribution of
the residuals. Multivariable linear regressions were conducted with the three cost categories as
dependent variables and non-adherence (rank tranformed), baseline anxiety, baseline depres-
sion, number of comorbidities, education level, baseline disease activity as measured with the
DAS28, age, gender and diagnosis as possible predictors. Predictors other than non-adherence
were chosen based on previous research (e.g. anxiety and depression are well known predictors
of healthcare costs). Furthermore, age and the number of comorbidities, as well as baseline dis-
ease activity were chosen as possible predictors since they are expected to affect healthcare
Non-adherence to DMARDs related to hospital costs
PLOS ONE | DOI:10.1371/journal.pone.0171070 February 2, 2017 5 / 14
costs. Current standard care guidelines differ per diagnosis and thus may indirectly affect
healthcare costs and is therefore a covariate. Because of the explorative character of the analy-
sis, we choose to enter all covariates in the multivariable regression at once. For the association
between non-adherence and costs, x-rays of the hand and feet were not included, because they
were taken for most patients, but sometimes just within the one-year timeframe and some-
times just outside the timeframe. This could otherwise lead to an over- or underestimation of
the associations between variables and costs. They were, however taken into account in the
description of the costs.
To visualize the association between non-adherence and costs, non-adherence was catego-
rized per 0.05 non-adherence proportion, resulting in an ordinal scale with 20 categories. The
mean patient costs were plotted per non-adherence category.
Non-adherence was also dichotomized using an 80% adherence cut-off. The proportional
distribution of costs were visualized in pie charts for adherent and non-adherent patients.
Mann-Whitney U tests were used to compare the median costs per category for adherent and
non-adherent patients.
Missing data
Patients were excluded from analysis when a patient became lost to follow up in the clinic, and
the hospital files did not include the healthcare consumption of the whole year. For some patients,
adherence data was incomplete because of lost to follow up in the study. If a patient had less than
one month of adherence data, the patient was excluded from analysis. For patients who had less
than one year monitoring data, the mean underuse proportion for the observed amount of days
was used in the analysis and was thus held to be constant for the remainder of the study period.
We also did a complete case analysis including only patients with more than 11 months of adher-
ence observations to check the robustness of our findings. The disease activity from patients who
were lost to follow up from the study was extracted from the patient files.
A p-value below 0.05 was considered as statistical significant, and all analyses were per-
formed using SPSS, version 21.0 (IBM Corp. released 2012. IBM SPSS Statistics for Windows,
Version 21.0. Armonk, NY: USA).
Results
Patients
Of the 275 invited patients, 206 were willing to participate. Twelve patients were lost to follow
up either in the clinic or during the study period and were excluded from analysis, which left
194 patients with complete cost data (Fig 1). Of the 206 patients who were included in the
study, for 158 (81.4%) patients, 1-year adherence data was available, for 173 patients, more
than 200 days of adherence monitoring data was available.
In Table 1, the demographic and disease characteristics of the study population are pre-
sented. Most patients (74.2%) had rheumatoid arthritis. There were no statistical significant
differences between those patients lost to follow up and patients that completed the cohort,
except for the mean HADS anxiety score, which is much higher for the patients who became
lost to follow up than for the patients with complete follow up (10.0 versus 5.4; p = 0.015).
Health care costs
The average costs for the rheumatology outpatient clinic over the one-year period are €
1455.76 (SD €2402.04), the average one-year costs including referrals are € 1620.47 (SD €
2471.14) and the average total costs for this patient group are approximately € 2117.25 (SD €
Non-adherence to DMARDs related to hospital costs
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3020.32) per year. As expected, among the patients, there was high variability in health care
consumption, which results in skewed data. The number of patients using the various types of
health care is given in Table 2. The mean number of rheumatology visits is 4.64 (range 2–11)
and the mean number of specialized rheumatology nurse visits is 3.2 (range 0–5). Of the imag-
ing modalities, x-rays were mostly used in the rheumatology outpatient clinic (83.7%), fol-
lowed by ultrasound (10.5%). Therapeutic procedures in the rheumatology outpatient clinic
only consist of intra-articular or intra-muscular corticosteroid injections.
Referrals to other specialists by rheumatologists were given to 75 patients (38.7%), ranging
from 1 to 4 different specialists. Most referrals were to dermatology (16), pulmonary specialists
(12), eye care specialists (12) and orthopedic surgeons (14). Diagnostic procedures in the cate-
gory ‘rheumatology referrals’ were mostly for tuberculosis screening for patients who needed a
step up in therapy to biological use.
Sixty-three patients (32.5%) went to other medical specialists for comorbidities, ranging
from 1 to 8 different specialists per patient. Most occurring specialist visits for comorbidities
were surgery (14), cardiology (10), eye care (8), dermatology (8), and internal medicine (8).
Table 1. Demographic and disease characteristics and adherence percentages.
Total (n = 206) Patients with 1-year follow up (n = 194) Patients lost to follow up (n = 12)
Age in years, mean (SD) 53,7 (14.2) 54 (14) 46.3 (16.4)
Gender, female, n (%) 130 (63.1) 123 (63.4) 7 (58.3)
Type of hospital, n (%)
• General
• Academic
175 (84.9)
31 (15.1)
165 (85.1)
29 (14.9)
10 (83.3)
2 (16.7)
Diagnosis, n (%)
• RA
• PSA/ arthritis with Crohn
• other
153 (74.2)
43 (20.9)
10 (4.9)
145 (75.9)
41 (21.1)
8 (4.1)
8 (66.7)
2 (16.7)
2 (16.7)
Baseline DAS28, mean(SD) 4.24 (1.36) 4,26 (1,36) 3.87 (1.43)
Baseline HAQ, median (IQR) 0.75 (0.29–1.13) 0.75 (0.25–1.13) 0.94 (0.69–1.34)*
Education level, n (%)
• Low
• Medium
• High
87 (42.2)
63 (30.6)
43 (20.9)
85 (43.8)
61 (31.4)
41 (21.1)
2 (33.3)*
2 (33.3)*
2 (33.3)*
HADS anxiety, mean SD 5.6 (4.5) 5.4 (4.4) 10 (5.3)*
HADS depression, mean SD 4.5 (3) 4.5 (3) 5.6 (3.4)*
Medication characteristics
Subcutanuous MTX, n (%) 39 (18.9) 37 (19.1) 2 (16.7)
Use of biologicals, n (%) 20 (9.7) 19 (9.8) 1 (8.3)
Mean 1-year non-adherence proportion (1 = non-adherent)
• MTX
• PRED
• SSZ
• HCQ
• ARA
0.3 (n = 194) 0.14 (n = 184) # (n = 10)
0.17 (n = 70) 0.12 (n = 65) # (n = 5)
0.22 (n = 31) 0.17 (n = 28) # (n = 3)
0.19 (n = 47) 0.15 (n = 45) # (n = 2)
0.03 (n = 2) 0.03 (n = 2) -
Abbreviations: DAS28: 28 joint count Disease Activity Score; HAQ: Health Assessment Questionnaire; DMARDs: Disease-modifying Anti-Rheumatic
Drugs; MTX: methotrexate, PRED: prednisone; SSZ: sulfasalazine; HCQ: hydroxychloroquine; ARA: arava
#: no adherence data was available
*6 patients had missing data
doi:10.1371/journal.pone.0171070.t001
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Non-adherence
Adherence differed per DMARD type. Using an 80% adherence cut-off, for MTX, 77.7% of
patients were adherent, as for hydroxychloroquine 77.8% were adherent. For prednisone,
80.0% of patients were adherent and for sulfasalazine, 71.4% were adherent.
Most patients started treatment with a combination of 2 DMARDs. During the first year of
treatment, 20 patients (10.2%) were switched to biologic DMARDs and 40 patients (20.4%)
were switched from oral to subcutaneous use of MTX.
Fig 2 depicts that as the adherence percentage decreases from 100% to 60% (40% of the
amount of medication not taken), the mean costs increase as well. However, this relation dis-
appears when patients are more than 40% non-adherent. Note that the patients who are more
than 40% non-adherent are a small minority; the overall study population is adherent: 90.7%
of the patients are between 100 and 60% adherent. More than 75% of the study population is
more than 80% adherent. The increase in costs with the increase of non-adherence seems to be
driven by the costs of anti-TNF. This is probably because some non-adherent patients start
using anti-TNF early, and these drugs are substantially higher priced.
Fig 3 depicts the distribution of the costs for adherent and non-adherent patients. An
adherence cut-off point of 80% is used. Patients who are less than 80% adherent make more
costs for anti-TNF. In all three cost categories, patients who are less than 80% adherent have
relatively more costs for hospital admissions than adherent patients. However, the medians of
the costs for anti-TNF do not significantly differ.
Table 2. Components of healthcare costs for early arthritis.
Rheumatology outpatient clinic Mean costs Rheumatology referrals Mean costs Comorbidities Mean costs
Consultations with medical specialist
No. of patients 196 (100%) 74 (37.8%) 62 (31.6%)
Mean no. per patient ± sd 4.6 ± 1.8 € 245.87 3.2 ± 3.4 € 295.24 4.3 ± 4.6 € 401.09
Consultations with specialized nurse/nurse practitioner
Mean no. per patient ± sd 3 ± 2.51 € 100.70 N/A N/A
Imaging modalities
No. of patients 84 (42.9%) 17 (8.8%) 34 (17.5%)
Mean no. per patient ± sd 3.1 ± 2.0 € 198.94 2.12 ± 1.5 € 295.86 2.12 ± 1.95 € 254.28
Medical procedures
Diagnostic procedures
No. of patients 11 (5.7%) 40 (20.6%) 27 (13.9%)
Mean no. per patient ± sd 1.18 ± 0.4 € 122.59 1.8 ± 1.3 € 70.65 1.59 ± 1.0 € 162.67
Therapeutic procedures
No. of patients 52 (26.8%) 2 (1%) 3 (1.5%)
Mean no. per patient ± sd 1.44 ± 0.7 € 8.54 15 ± 7.0 # 2 ± 1 ##
ER visits
No. of patients 2 (1%) 3(1.5%) 16 (8.2%)
Mean no. per patient ± sd 1 ± 0 € 163.75 1 ± 0 € 163.75 1.31 ± 0.6 € 214.92
Hospital admissions (including day admissions)
No. of patients 9 (4.6%) € 6082.38 4 (2.1%) € 607.84 22 (11.3%) € 2488.24
Laboratory tests
Mean no. per patient ± sd 8 ± 4.6 € 146.93 N/A N/A
Abbreviations: SD: standard deviation, N/A: not applicable, ER: emergency room
# no unit price available
## Not all the unit prices were available (2 out of 3 not available)
doi:10.1371/journal.pone.0171070.t002
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Associations with costs
Table 3 shows the results of the multivariate regression of non-adherence on costs. Non-adher-
ence is, corrected for other covariates, statistically significant associated to higher total costs,
higher costs made at the rheumatology outpatient clinic, and higher rheumatology-related
costs.
In a sensitivity analysis, we only included patients with complete adherence data (more
than 11 months of observed data) in the regression analyses. Non-adherence remained statisti-
cally significant associated to all three cost categories.
Discussion
This is the first study to find evidence that non-adherence is associated with hospital health
care costs in the first year of treatment of arthritis. In addition to non-adherence, baseline
symptoms of anxiety are associated to hospital health care costs.
The mean number of visits to the rheumatologist is slightly less than previous studies on
health care consumption in a rheumatoid arthritis cohort, that found an average number of
5.7 visits to the rheumatologist per year [4]. However, in this cohort, not the health care con-
sumption in the first year of treatment, but that of established patients was investigated. Health
care consumption is expected to be higher in the first year of treatment than in the years there-
after, since treatment has to be tailored and adjusted in the first period of disease, and therefore
more visits to the rheumatologist are needed.
The percentage of patients referred to other specialists for arthritis- or DMARD related
symptoms was 38.7%. The percentage of patients with comorbidities in our cohort was 32.5%,
Fig 2. Association between costs and adherence percentage.
doi:10.1371/journal.pone.0171070.g002
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which is slightly higher than found in other studies (27%) [21], which might explain why our
costs in the first years were higher. The difference in comorbidities can be due to the fact that
we measured comorbidities as the number of different medical specialists visited instead of the
number of additional diagnoses.
Non-adherence is, corrected for other covariates, associated with higher healthcare costs at
the rheumatology outpatient clinic, higher rheumatology-related costs, and higher total health-
care costs. From the data that we collected, it does not appear that patients who are non-adher-
ent make more costs in terms of visits to health care specialists or that they are referred more
often to healthcare specialists: the relationship between non-adherence and costs found is
related to higher medication costs. It seems that patients who were switched to subcutaneous
methotrexate or anti-TNF were non-adherent to their oral DMARD medication. It could be
that because of non-adherence, their disease activity escalated and that they were switched
sooner to more expensive medicines such as anti-TNF.
Although there is not much empirical research about the relation between non-adherence
and costs in rheumatology in practice, numerous authors suggest that being non-adherent
Fig 3. Percentage distribution of costs categories for patients 80% or more adherent and patients less than 80% adherent.
doi:10.1371/journal.pone.0171070.g003
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would lead to higher healthcare cost [5, 10, 13, 22, 23]. We could confirm this suggestion for
most patient that are non-adherent, but for patients who are more than 40% non-adherent,
costs seem to be lower. These patients do not significantly differ from the more adherent
patients in diagnosis, but it might be that these patients have a lower baseline disease activity.
Over the course of one year, the disease activity of these patients is slightly lower than the dis-
ease activity of the more adherent patients. It might be that being non-adherent is a response
to experiencing low disease activity. It might also be that these patients do not have to visit the
rheumatologist as often because of mild disease.
Because this is a cross-sectional study, there is uncertainty about the direction of the causal-
ity between healthcare costs and non-adherence. It might be that higher healthcare costs lead
to non-adherence, but this seems unlikely since in the Netherlands, all rheumatologist care is
covered by healthcare insurance. All patients have healthcare insurance and therefore have the
same healthcare costs. Confounding is however a likely scenario. It could for instance be that
medication side effects result in both high costs and non-adherence.
In addition to non-adherence, there is also a relationship between baseline symptoms of
anxiety and healthcare costs. The relationship between healthcare costs and anxiety is well-
known [24, 25].
We were not able to include all costs in our analysis. We had only access to hospital files,
and have no data on out of pocket costs and costs of productivity loss. Patient with recent
onset arthritis are often on sick leave because of high disease activity, which would contribute
to productivity losses and thus to higher societal costs [26–28]. Other studies have suggested
that non-adherence does decrease work productivity [29, 30]. It could be that if we had access
to this data of productivity loss, the association between non-adherence and costs might have
been larger. Also, costs for supplemental drugs to prevent NSAID induced symptoms and over
the counter medication were not measured. They might also attribute to higher costs in RA
[27, 31].
MEMS is up till now the best indirect method to measure non-adherence, and is considered
as a ‘gold standard’. Because it measures behavior ‘real time’, it is a very accurate measure. The
disadvantage of using MEMS, is that it does not prove ingestion of medication. Participants
were instructed to use the MEMS vials for each separate DMARD, but we cannot be sure that
they all took their DMARDs from the MEMS vials all the time, which might lead to an
Table 3. Multivariable linear regression analysis of possible predictors of costs per cost category.
Rheumatology outpatient clinic
costs
Rheumatology-related costs Total hospital costs
Standardized Beta p-value Standardized Beta p-value Standardized Beta p-value
Non-adherence 0.253 0.001 0.181 0.020 0.188 0.006
Age 0.146 0.106 0.166 0.069 0.212 0.008
Gender 0.061 0.430 0.032 0.680 0.045 0.510
Education level -0.019 0.821 -0.043 0.607 -0.046 0.534
Baseline HADS anxiety 0.217 0.025 0.208 0.033 0.193 0.025
Baseline HADS depression 0.047 0.628 0.035 0.716 0.021 0.808
Baseline DAS28 0.039 0.638 0.122 0.143 0.128 0.082
PsA 0.326 0.061 0.255 0.146 0.310 0.044
RA 0.300 0.084 0.198 0.257 0.232 0.132
Nr of comorbidities 0.077 0.320 0.025 0.752 0.408 <0.001
Abbreviations: HADS: Hospital Anxiety and Depression Scale, PsA: psoriatic arthritis, RA: rheumatoid arthritis, DAS28: 28-joint count disease activity score
doi:10.1371/journal.pone.0171070.t003
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overestimation of adherence. Also, we could not measure adherence from patients who were
switched to subcutaneous MTX or biologicals, because these medicines do not fit in the medi-
cation vial. Subcutaneous MTX is prescribed when the patient experiences too many gastro-
intestinal side-effects from oral MTX. Patients who used subcutaneous MTX were asked to put
their folic acid in the MEMS vial, so that adherence could still be measured. Furthermore, of
the 39 patients who received subcutaneous MTX, 21 also used an additional DMARD to which
adherence could still be measured. Biologicals are in the first year of treatment prescribed
when the target of treatment was not reached with synthetic DMARDs and there are prognos-
tically unfavorable factors present [6]. Biologicals are mostly added to the treatment with syn-
thetic DMARDs, thus adherence to the synthetic DMARDs could still be measured. Electronic
measurement of adherence is sometimes seen as an intervention itself and might increase
adherence behavior, but this effect is regarded as small [32].
The outcomes of this study might be subjected to the ‘adherer effect’ [33]. Patients who
adhere to the rheumatologists’ prescription have better disease outcomes, regardless of the
underlying treatment and are therefore expected to have less health care costs. This theory is
based on the finding that behaviors of adherent people are different from the behaviors of non-
adherent people. Adherent people have better global health outcomes, since they have more
healthy lifestyles, do not engage in risky behaviors and are more adherent to nonpharmacologic
prescriptions [34, 35]. Patients who agreed to participate in this cohort study are probably more
adherent than the general patient population, which is also known from other studies [14]. This
means that in daily practice the effect of non-adherence on costs might be larger.
In addition, patients who became lost to follow up were or became probably less adherent
than the patients who completed follow up. The patients in this cohort are rather adherent to
their medication and there is little variation in adherence. This makes it more difficult to study
the association between non-adherence and hospital costs.
This study shows that there is an association between non-adherence and costs. This sug-
gests that improving adherence is associated with savings. Most money can be saved in medi-
cation costs. The mean medication costs for patients who are switched to anti-TNF therapy,
are almost 30 times more than the costs for patients who use synthetic DMARDs.
Our findings address the need to improve adherence, because money is being wasted and
potentially beneficial medication is discarded. It is important to study which patients are at
risk for non-adherence, so that interventions to improve adherence can be targeted. While
there remains uncertainty about which patients are at risk and how to intervene on adherence
behavior, rheumatologists should at least be aware that patients might be non-adherent to
therapy. Focusing on the way they communicate with the patient is important, because the
patient-doctor relationship is an inescapable factor in establishing good adherence behavior
[36]. The rheumatologist should build up towards a trustworthy relationship with the patient
so that communication about non-adherence can take place and the importance of adherence
to the treatment can be addressed. This is not only better for the patient, but will also save
money from a societal perspective.
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